SCHEMBL17812902

SCHEMBL17812902

Cc1cccc(-c2nc(Nc3ccccc3)cc(NC(C)C)n2)n1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 6/20 0.59
ABCG2 Q9UNQ0 6/20 0.53
ABCC1 P33527 4/20 0.53
ABCB1 P08183 3/20 0.53
MAPK14 Q16539 1/20 0.45
KMT2A Q03164 3/20 0.44
KCNH3 Q9ULD8 3/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 1/20 0.43
NPC1 O15118 1/20 0.43
GBA1 P04062 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16391941 0.86 ABCG2 (0.52) TGFBR1ABCG2ABCC1ABCB1KMT2A
SCHEMBL16391870 0.86 ABCG2 (0.52) TGFBR1ABCG2ABCC1ABCB1KMT2A
SCHEMBL17812917 0.85 TGFBR1 (0.57) TGFBR1ABCG2ABCC1ABCB1MAPK14
SCHEMBL16391950 0.84 TGFBR1 (0.47) TGFBR1ABCG2ABCC1ABCB1CYP1A2
SCHEMBL21977577 0.84 TGFBR1 (0.47) TGFBR1ABCG2ABCC1ABCB1CYP1A2
SCHEMBL17812899 0.84 CYP1A2 (0.52) TGFBR1ABCG2ABCC1ABCB1MAPK14
SCHEMBL16391640 0.83 CYP1A2 (0.63) ABCG2ABCC1ABCB1MAPK14KMT2A
SCHEMBL16391780 0.83 IDH1 (0.61) ABCG2ABCC1ABCB1KMT2ACYP1A2
SCHEMBL16392243 0.81 ABCG2 (0.58) ABCG2ABCC1ABCB1KMT2AKCNH3
SCHEMBL17812901 0.81 TGFBR1 (0.46) TGFBR1ABCG2ABCC1ABCB1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158230-A1 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER SERVIER PHARMACEUTICALS LLC 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158230-A1 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER IDH2, IDH3B, IDH3A TGFBR1 3893/4885ABCG2 889/4885ABCC1 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.